放疗增强鼻咽癌CCL22表达并招募CCR4+CD8 T细胞
该研究利用鼻咽癌患者来源异种移植瘤、细胞系及TCGA数据,发现放疗后CCL22在肿瘤、上清、细胞裂解液及患者血清中显著升高。CCL22或CCR4高表达与细胞毒性T淋巴细胞特征正相关且预后更好,CCL22可趋化CCR4+效应CD8 T细胞。
要点
- 放疗后鼻咽癌CCL22表达与释放显著增加。
- CCL22或CCR4高表达与更好预后相关。
- CCL22可招募CCR4+效应CD8 T细胞。
核心结论
- 放疗增强鼻咽癌细胞释放CCL22,促进CCR4+效应CD8 T细胞迁移,可能与放疗介导的抗肿瘤免疫部分相关。
研究设计与样本
- 研究使用鼻咽癌患者来源异种移植瘤、细胞系、健康志愿者外周血分选的CCR4+CD8 T细胞及TCGA来源的bulk RNA-seq或单细胞RNA-seq数据集。
- 对异种移植瘤或细胞系照射后收集样本进行bulk RNA测序或CCL22表达与释放检测。
- 在有无照射条件下,对过表达CCL22或重组CCL22处理的细胞评估恶性表型与放射敏感性。
- 用酶联免疫吸附试验检测上清、细胞裂解液或血清样本中的CCL22。
主要发现
- 照射后的患者来源异种移植瘤、鼻咽癌细胞系上清和细胞裂解液及接受放疗患者血清中CCL22显著增加。
- 过表达CCL22或重组CCL22处理未改变肿瘤细胞的恶性表型。
- Kaplan-Meier分析显示CCL22或其受体CCR4与细胞毒性T淋巴细胞特征正相关,且CCL22或CCR4高表达与鼻咽癌患者更好预后相关。
- 单细胞RNA-seq数据集分析显示CCR4表达于多种T细胞亚型,包括效应CD8 T细胞。
- 趋化实验表明CCR4+CD8 T细胞可被CCL22处理招募。
临床怎么用
- 放疗后CCL22升高可能促进CCR4+效应CD8 T细胞招募,提示其与放疗抗肿瘤免疫相关。
- CCL22或CCR4高表达与鼻咽癌更好预后相关,或可作为免疫相关预后参考。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Radiation therapy elicits profound alterations in gene expression in tumor cells. This study aims to determine the dynamic changes in the expression of immunity-associated genes in nasopharyngeal carcinoma (NPC) cells upon radiation therapy. METHODS AND MATERIALS: The study was performed using NPC patient-derived tumor xenograft tumors, cell lines, CCR4+ CD8 T cells sorted from peripheral blood mononuclear cells of healthy volunteers, and TCGA-derived bulk RNA-seq or single-cell RNA-seq (scRNA-seq) data sets. Patient-derived tumor xenograft tumors or cell lines were irradiated and collected for bulk RNA sequencing or for CCL22 expression and release detection. Malignant phenotypes and radiosensitivity were assessed in cells with or without overexpression of CCL22 or recombinant CCL22 treatment in the presence or absence of irradiation. TCGA data sets were used for uncovering CCR4 status in subtypes of T cells. CCL22 in supernatants, cell lysates, or serum samples was measured with enzyme-linked immunosorbent assay. RESULTS: CCL22 was significantly increased in the irradiated patient-derived tumor xenograft tumors, the supernatants and cell lysates collected from irradiated NPC cell lines, and the serum of patients who received radiation therapy. No alterations of malignant phenotypes were found in tumor cells with CCL22 overexpression or recombinant CCL22 treatment. Kaplan-Meier analysis revealed that CCL22 or its receptor CCR4 positively correlated with cytotoxic T lymphocyte signatures, and high expression of CCL22 or CCR4 was associated with better prognosis for patients with NPC. scRNA-seq data set-based analysis demonstrated that CCR4 was expressed in multiple subtypes of T cells, including effector CD8 T cells. Chemotaxis assay indicated that CCR4+ CD8 T cells could be recruited by CCL22 treatment. CONCLUSION: The radiation-enhanced release of CCL22 from NPC cells promotes migration of CCR4 + effector CD8 T cells, which might partially be associated with radiation therapy-mediated antitumor immunity.
引用
- Li H, Chen X, Zeng W, et al. Radiation-Enhanced Expression of CCL22 in Nasopharyngeal Carcinoma is Associated With CCR4+ CD8 T Cell Recruitment. Int J Radiat Oncol Biol Phys. 2020. PMID: 32428547. doi:10.1016/j.ijrobp.2020.05.001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。